Receptor tyrosine kinases and inhibitors in lung cancer.
Receptor tyrosine kinases and inhibitors in lung cancer.
复制标题
DOI：
10.1100/tsw.2004.117
复制
发表时间：
2004-08-06
影响因子：
--
通讯作者：
Salgia R
中科院分区：
文献类型：
--
作者：
Pisick E;Jagadeesh S;Salgia R
肺癌是一种致死率和致残率都很高的疾病。大多数肺癌病例是由于非小细胞癌，其中16%的病例是小细胞癌。细胞水平上的生物学在许多层面上都是令人感兴趣的。了解细胞通路有助于进一步增强我们对肺癌细胞如何存活、增殖和转移的认识。位于细胞膜上的受体酪氨酸激酶（receptor tyrosine kinases，RTK）作为肺癌靶向治疗的靶点，正引起人们极大的兴趣。这篇综述将讨论与肺癌有关的RTK和正在测试的新疗法。我们将具体讨论受体如表皮生长因子受体、c-Kit受体、VEGF受体、c-Met受体、胰岛素生长因子受体和Eph受体。针对特定RTK的抑制剂处于各种临床前和临床试验中，这将被详细描述。
Lung cancer is a deadly disease with high mortality and morbidity. Most cases of lung cancer are due to non-small cell carcinoma, with 16% of cases being small cell carcinoma. The biology at a cellular level is of interest at many levels. Knowing cellular pathways helps to further enhance our knowledge of how lung cancer cells survive, proliferate, and metastasize. The receptor tyrosine kinases (RTKs) located at the cellular membrane are becoming of great interest as sites for targeted therapies for lung cancers. This review will discuss the RTKs that are involved in lung cancers and the newer therapies that are being tested. We will specifically discuss receptors such as epidermal growth factor receptor, c-Kit receptor, VEGF receptor, c-Met receptor, insulin growth factor receptor, and Eph receptor. The inhibitors against the specific RTKs are in various preclinical and clinical trials, and this will be detailed.